I just found the information below about GenOne fr
Post# of 72440
(Total Views: 452)
Posted On: 03/20/2020 4:18:52 PM
I just found the information below about GenOne from an October 2018 article - my earlier post stated "hydroxychloroquine is showing promising results especially when combined with an antibiotic". Could it be?
4) Can you provide a short overview of your product pipeline?
DNA-based vaccines in clinical development include those against Zika virus, the Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Hepatitis C. Our vaccines against the Severe Fever and Thrombocytopenia syndrome (SFTS) and Varicella Zoster have shown promising results in vitro pre-clinical studies.
DNA-based therapeutics in pre-clinical development include plasmid DNA-expressed Factor VIII as a prophylactic treatment for hemophilia A, Plasmid DNA-expressed monoclonal antibody for hepatitis B immunologlobulin, Plasmid DNA expressed sc4D5-VEGF-Trap for multiple oncologic targets, and plasmid DNA expressed anti-Her2 monoclonal antibody. We have shown that the plasmid DNA -expressed anti-Her2 antibody is equally or more effective in treating Her2 positive breast cancer in a xenograft mouse model of disease (Kim et al., Cancer Gene Therapy 2016; 23(10) 341–7).
GeneOne recently acquired GLS-1027, a small molecule that has been shown as active in multiple pre-clinical animal models of inflammatory and autoimmune diseases. GeneOne has also in-licensed from the University of Pennsylvania the use of quinine as a bitter taste receptor agonist for the treatment of sinus infection.
The MERS-CoV DNA vaccine moved into Phase II trials in the summer of 2018. GLS-1027 and quinine are expected to enter into Phase II trials within the next year. mRNA vaccine products are in the design phase.
4) Can you provide a short overview of your product pipeline?
DNA-based vaccines in clinical development include those against Zika virus, the Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Hepatitis C. Our vaccines against the Severe Fever and Thrombocytopenia syndrome (SFTS) and Varicella Zoster have shown promising results in vitro pre-clinical studies.
DNA-based therapeutics in pre-clinical development include plasmid DNA-expressed Factor VIII as a prophylactic treatment for hemophilia A, Plasmid DNA-expressed monoclonal antibody for hepatitis B immunologlobulin, Plasmid DNA expressed sc4D5-VEGF-Trap for multiple oncologic targets, and plasmid DNA expressed anti-Her2 monoclonal antibody. We have shown that the plasmid DNA -expressed anti-Her2 antibody is equally or more effective in treating Her2 positive breast cancer in a xenograft mouse model of disease (Kim et al., Cancer Gene Therapy 2016; 23(10) 341–7).
GeneOne recently acquired GLS-1027, a small molecule that has been shown as active in multiple pre-clinical animal models of inflammatory and autoimmune diseases. GeneOne has also in-licensed from the University of Pennsylvania the use of quinine as a bitter taste receptor agonist for the treatment of sinus infection.
The MERS-CoV DNA vaccine moved into Phase II trials in the summer of 2018. GLS-1027 and quinine are expected to enter into Phase II trials within the next year. mRNA vaccine products are in the design phase.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼